MDACC Study No:2011-0838 ( NCT No: NCT01214603)
Title:Phase 2 Study of LY2090314 in Patients with Acute Leukemia
Principal Investigator:Gautam Borthakur
Treatment Agent:LY2090314
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if LY2090314 can help to
control the disease in patients with AML. The safety and difference in dose
levels of this drug will also be studied.

LY2090314 is a drug that stops DNA (the genetic material of cells) growth in
which leukemias are dependent upon for their survival.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:LY2090314
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eli Lilly and Company
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults